Dr Reddy's Laboratories (Dr Reddy's Laboratories) 5-Year EBITDA Growth Rate : 18.90% (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Dr Reddy's Laboratories 5-Year EBITDA Growth Rate?

Dr Reddy's Laboratories's EBITDA per Share for the three months ended in Dec. 2023 was $1.62.

During the past 12 months, Dr Reddy's Laboratories's average EBITDA Per Share Growth Rate was 21.70% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 33.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 18.90% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 5.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Dr Reddy's Laboratories was 154.40% per year. The lowest was -44.70% per year. And the median was 9.35% per year.

Competitive Comparison of Dr Reddy's Laboratories's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dr Reddy's Laboratories's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's 5-Year EBITDA Growth Rate falls into.

Dr Reddy's Laboratories 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Dr Reddy's Laboratories (NYSE:RDY) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Dr Reddy's Laboratories 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Reddy's Laboratories (Dr Reddy's Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (NYSE:RDY) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

DRREDDY:India 500124:India RDDA:Germany RDDA:Germany R1DY34:Brazil

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.